Wells Fargo & Company Has Lowered Expectations for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price target dropped by stock analysts at Wells Fargo & Company from $28.00 to $25.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 32.66% from the company’s previous close.

Several other analysts have also issued reports on the company. Barclays cut their price target on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. Stifel Nicolaus cut their target price on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. Raymond James dropped their price objective on Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Robert W. Baird dropped their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Finally, UBS Group reiterated a “neutral” rating and set a $25.00 price objective (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and an average target price of $26.85.

Avantor Price Performance

AVTR traded down $0.32 during trading on Monday, reaching $18.85. 1,593,166 shares of the company were exchanged, compared to its average volume of 5,055,766. The company’s 50-day moving average is $21.73 and its two-hundred day moving average is $23.47. Avantor has a 12-month low of $18.49 and a 12-month high of $28.00. The company has a market cap of $12.83 billion, a price-to-earnings ratio of 40.66, a P/E/G ratio of 3.87 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter last year, the business posted $0.22 EPS. Research analysts forecast that Avantor will post 0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avantor

A number of institutional investors and hedge funds have recently modified their holdings of AVTR. Public Employees Retirement System of Ohio lifted its stake in shares of Avantor by 34.1% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 346,822 shares of the company’s stock worth $8,972,000 after purchasing an additional 88,205 shares during the period. Perpetual Ltd lifted its stake in shares of Avantor by 38.7% during the 4th quarter. Perpetual Ltd now owns 1,766,882 shares of the company’s stock worth $37,228,000 after purchasing an additional 493,408 shares during the period. New York State Teachers Retirement System purchased a new position in shares of Avantor during the 3rd quarter worth $8,473,000. Everence Capital Management Inc. purchased a new position in shares of Avantor during the 4th quarter worth $555,000. Finally, Teachers Retirement System of The State of Kentucky raised its position in shares of Avantor by 45.8% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 723,178 shares of the company’s stock worth $18,708,000 after buying an additional 227,200 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.